Cardima to Present at the A.G. Edwards' Panel and Interactive Discussion on Emerging Medical Technology.Business Editors/Health & Medical Writers FREMONT, Calif.--(BW HealthWire)--Feb. 12, 2002 Cardima(R), Inc. (Nasdaq:CRDM CRDM Control Rod Drive Mechanism CRDM Centre for Rapid Design and Manufacture (Buckinghamshire Chilterns University) CRDM Cumann Rince Dea Mheasa (Irish dancing organisation) ) -- developer of the REVELATION(TM) Tx and the REVELATION Helix(TM) microcatheter systems -- today announced that Ronald Bourquin, Cardima's chief financial officer, will present at A.G. Edwards' inaugural Panel and Interactive Discussion on Emerging Medical Technology: Atrial Fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. , being held in Boston on Tuesday, February 12, 2002. A webcast of Mr. Bourquin's presentation will be available on the Company's website at www.cardima.com for 30 days, beginning on February 12th, 2002. Cardima, Inc. developed its patented, unique series of REVELATION microcatheter systems for the mapping and treatment of atrial fibrillation (AF), which the Company believes is a potential $6 billion market that is poorly served by current treatment alternatives. AF afflicts an estimated 4.5 million people worldwide. The REVELATION series of microcatheters are minimally invasive, single-use microcatheters for potentially curing AF. Enrollment in a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA study for the Company's REVELATION Tx linear ablation ablation /ab·la·tion/ (-shun) 1. separation or detachment; extirpation; eradication. 2. removal or destruction, especially by cutting. ab·la·tion n. microcatheter system is underway in the U.S. The Company is targeting U.S. approval for this device before the end of 2002. The Company's REVELATION Helix system received CE Mark approval in December 2001. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 and Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for the quarters ended March 31, June 30 and September 30, 2001 filed with the Securities and Exchange Commission on March 22, May 14, August 14, 2001 and November 14, 2001, respectively. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion